MAM
Vizeum is media consultant for BSA Hercules Chennai Cycling 2012
MUMBAI: Vizeum has been appointed as the media consultant for BSA Hercules Chennai Cycling 2012, scheduled to be held on the 26 February.
CRX Sports, a sports event management company with its area of expertise in cycling, is the organiser and promoter of the event.
CRX Sports MD Rohit Kuttappa said “We have had a running relationship with Vizeum through our association with TI Cycles, a Vizeum client. Their thinking ability and contributions always impressed us. When we needed professional inputs to help us with the ‘BSA Hercules Chennai Cycling 2012’ event, we knew we didn’t need to go beyond Vizeum.”
Vizeum MD Indian sub-continent S Yesudas added, “I have pleasure in inviting CRX Sports Ventures into the Aegis Media family. We sincerely thank the client management for their faith in us. This once again comes as fitting tribute to the Vizeum way of contributions to clients’ businesses. This engagement will be handled out of our Chennai office under the leadership of Vizeum GM –South E M Sreeneelakandhan, I also take this opportunity to congratulate Team Vizeum Chennai on this win”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
